Insights into the future of gastric acid suppression (Q37588492)

21 August 2017

1 reference

title

Insights into the future of gastric acid suppression (English)

1 reference

21 August 2017

2

Nicholas J Talley

1 reference

21 August 2017

Kenneth R DeVault

1

1 reference

PubMed ID

19713987

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Nature Reviews Gastroenterology & Hepatology

21 August 2017

1 reference

21 August 2017

6

1 reference

21 August 2017

9

1 reference

21 August 2017

524-532

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2009.125

21 August 2017

0 references

cites work

Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

A novel histamine 2(H2) receptor antagonist with gastroprotective activity. II. Synthesis and pharmacological evaluation of 2-furfuryl-thio and 2-furfurylsulfinyl acetamide derivatives with heteroaromatic rings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Pharmacology of proton pump inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Symptomatic gastroesophageal reflux: incidence and precipitating factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Appropriate acid suppression for the management of gastro-oesophageal reflux disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Effectiveness of proton pump inhibitors in nonerosive reflux disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Proton pump inhibitors: better acid suppression when taken before a meal than without a meal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

The choice of proton pump inhibitor: does it matter?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

In-vitro activity of lansoprazole against Helicobacter pylori

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

What every hepatologist should know about endocrinology: obesity, diabetes, and liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Importance of pH control in the management of GERD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Esomeprazole: a review of its use in the management of acid-related disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole--a preliminary study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Plasma direct injection high-performance liquid chromatographic method for simultaneously determining E3810 enantiomers and their metabolites by using flavoprotein-conjugated column

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Single-enantiomer drugs: elegant science, disappointing effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Review of immediate-release omeprazole for the treatment of gastric acid-related disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Can famotidine and omeprazole be combined on a once-daily basis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Liver injury caused by ebrotidine: a new example of the utility of the postmarketing surveillance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

31 March 2020

Gastric acid secretion

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

CCK receptor antagonists.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Acid suppression therapy: where do we go from here?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Chronic proton pump inhibitor therapy and the risk of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Effect of sulfated and non-sulfated gastrin and octapeptide-cholecystokinin on cat gall bladder in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Proton pump inhibitors and acute interstitial nephritis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Yellow fever vaccination and risk of spontaneous abortion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Long-term proton pump inhibitor therapy and risk of hip fracture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Calcium absorption and achlorhydria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Serum Iron, Ferritin, and Vitamin B12 During Prolonged Omeprazole Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Genetic determinants of response to clopidogrel and cardiovascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

The burden of gastrointestinal and liver diseases, 2006.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.125

Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis.

31 March 2020

1 reference

12 December 2020

Ascorbic acid chelates in iron absorption: a role for hydrochloric acid and bile

1 reference

12 December 2020

Evaluation of bioequivalence between a single-capsule formulation of esomeprazole 40 mg and acetylsalicylic acid 325 mg and the monotherapies given separately in healthy volunteers

1 reference

12 December 2020

Studies on the cytoprotective and antisecretory activity of ebrotidine. A review

1 reference

12 December 2020

Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study

1 reference

12 December 2020

Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus

1 reference

12 December 2020

Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial

1 reference

12 December 2020

Incidence and risk factors of diarrhoea in Dutch travellers: consequences for priorities in pre-travel health advice.

1 reference

12 December 2020

Prevention of chronic NSAID induced upper gastrointestinal toxicity

1 reference

12 December 2020

10.1038/NRGASTRO.2009.125

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19713987